These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30768833)

  • 1. Modeling graft loss in patients with donor-specific antibody at baseline using the Birmingham-Mayo (BirMay) predictor: Implications for clinical trials.
    Bentall A; Smith BH; Gonzales MM; Bonner K; Park WD; Cornell LD; Dean PG; Schinstock CA; Borrows R; Lefaucheur C; Loupy A; Stegall MD
    Am J Transplant; 2019 Aug; 19(8):2274-2283. PubMed ID: 30768833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor Specificity but Not Broadness of Sensitization Is Associated With Antibody-Mediated Rejection and Graft Loss in Renal Allograft Recipients.
    Wehmeier C; Hönger G; Cun H; Amico P; Hirt-Minkowski P; Georgalis A; Hopfer H; Dickenmann M; Steiger J; Schaub S
    Am J Transplant; 2017 Aug; 17(8):2092-2102. PubMed ID: 28245084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: Clinical presentation and implications for outcome.
    Senev A; Coemans M; Lerut E; Van Sandt V; Daniëls L; Kuypers D; Sprangers B; Emonds MP; Naesens M
    Am J Transplant; 2019 Mar; 19(3):763-780. PubMed ID: 30107078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of monitoring circulating donor-reactive memory B cells to characterize antibody-mediated rejection after kidney transplantation.
    Luque S; Lúcia M; Melilli E; Lefaucheur C; Crespo M; Loupy A; Bernal-Casas D; Gomà M; Jarque M; Crespo E; Montero N; Manonelles A; Cruzado JM; Gil-Vernet S; Grinyó JM; Bestard O
    Am J Transplant; 2019 Feb; 19(2):368-380. PubMed ID: 30085394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of pretransplant donor-specific antibodies on kidney allograft recipients with negative flow cytometry cross-matches.
    Kwon H; Kim YH; Choi JY; Shin S; Jung JH; Park SK; Han DJ
    Clin Transplant; 2018 Jun; 32(6):e13266. PubMed ID: 29676812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Significance of Pretransplant Donor-Specific Antibodies in the Setting of Negative Cell-Based Flow Cytometry Crossmatching in Kidney Transplant Recipients.
    Adebiyi OO; Gralla J; Klem P; Freed B; Davis S; Wiseman AC; Cooper JE
    Am J Transplant; 2016 Dec; 16(12):3458-3467. PubMed ID: 27140940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor-Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes Independently Predicts the Incidence of De Novo Donor-Specific HLA Antibodies Following Renal Transplantation.
    Lachmann N; Niemann M; Reinke P; Budde K; Schmidt D; Halleck F; Pruß A; Schönemann C; Spierings E; Staeck O
    Am J Transplant; 2017 Dec; 17(12):3076-3086. PubMed ID: 28613392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss.
    Schinstock CA; Cosio F; Cheungpasitporn W; Dadhania DM; Everly MJ; Samaniego-Picota MD; Cornell L; Stegall MD
    Am J Transplant; 2017 Jun; 17(6):1574-1584. PubMed ID: 27977905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kidney Intragraft Homing of De Novo Donor-Specific HLA Antibodies Is an Essential Step of Antibody-Mediated Damage but Not Per Se Predictive of Graft Loss.
    Nocera A; Tagliamacco A; Cioni M; Innocente A; Fontana I; Barbano G; Carrea A; Ramondetta M; Sementa A; Basso S; Quartuccio G; Klersy C; Bertocchi M; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Comoli P; Ginevri F
    Am J Transplant; 2017 Mar; 17(3):692-702. PubMed ID: 27501275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The results of HLA-incompatible kidney transplantation according to pre-transplant crossmatch tests: Donor-specific antibody as a prominent predictor of acute rejection.
    Kwon H; Kim YH; Kim JY; Choi JY; Shin S; Jung JH; Park SK; Han DJ
    Clin Transplant; 2019 May; 33(5):e13533. PubMed ID: 30864255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shared alloimmune responses against blood and transplant donors result in adverse clinical outcomes following blood transfusion post-renal transplantation.
    Hassan S; Regan F; Brown C; Harmer A; Anderson N; Beckwith H; Roufosse CA; Santos-Nunez E; Brookes P; Taube D; Willicombe M
    Am J Transplant; 2019 Jun; 19(6):1720-1729. PubMed ID: 30582278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
    Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
    Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De Novo Donor-Specific Human Leukocyte Antigen Antibody Screening in Kidney Transplant Recipients After the First Year Posttransplantation: A Medical Decision Analysis.
    Kiberd BA; Miller A; Martin S; Tennankore KK
    Am J Transplant; 2016 Nov; 16(11):3212-3219. PubMed ID: 27106124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolated v-lesion in kidney transplant recipients: Characteristics, association with DSA, and histological follow-up.
    Rabant M; Boullenger F; Gnemmi V; Pellé G; Glowacki F; Hertig A; Brocheriou I; Suberbielle C; Taupin JL; Anglicheau D; Legendre C; Duong Van Huyen JP; Buob D
    Am J Transplant; 2018 Apr; 18(4):972-981. PubMed ID: 29206350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.
    Eskandary F; Jilma B; Mühlbacher J; Wahrmann M; Regele H; Kozakowski N; Firbas C; Panicker S; Parry GC; Gilbert JC; Halloran PF; Böhmig GA
    Am J Transplant; 2018 Apr; 18(4):916-926. PubMed ID: 28980446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C1q-binding DSA and allograft outcomes in pediatric kidney transplant recipients.
    Hayde N; Solomon S; Caglar E; Ge J; Qama E; Colovai A
    Pediatr Transplant; 2021 Mar; 25(2):e13885. PubMed ID: 33131194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protocol Biopsies in Patients With Subclinical De Novo Donor-specific Antibodies After Kidney Transplantation: A Multicentric Study.
    Bertrand D; Gatault P; Jauréguy M; Garrouste C; Sayegh J; Bouvier N; Caillard S; Lanfranco L; Galinier A; Laurent C; Etienne I; Farce F; François A; Guerrot D
    Transplantation; 2020 Aug; 104(8):1726-1737. PubMed ID: 32732853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.
    Moreso F; Crespo M; Ruiz JC; Torres A; Gutierrez-Dalmau A; Osuna A; Perelló M; Pascual J; Torres IB; Redondo-Pachón D; Rodrigo E; Lopez-Hoyos M; Seron D
    Am J Transplant; 2018 Apr; 18(4):927-935. PubMed ID: 28949089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specificity, strength, and evolution of pretransplant donor-specific HLA antibodies determine outcome after kidney transplantation.
    Senev A; Lerut E; Van Sandt V; Coemans M; Callemeyn J; Sprangers B; Kuypers D; Emonds MP; Naesens M
    Am J Transplant; 2019 Nov; 19(11):3100-3113. PubMed ID: 31062492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure.
    Kannabhiran D; Lee J; Schwartz JE; Friedlander R; Aull M; Muthukumar T; Campbell S; Epstein D; Seshan SV; Kapur S; Sharma VK; Suthanthiran M; Dadhania D
    Transplantation; 2015 Jun; 99(6):1156-64. PubMed ID: 25629531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.